Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma

被引：0

作者：

V. E. Goldberg

T. Yu. Polyakova

N. O. Popova

V. V. Vysotskaya

E. I. Simolina

Yu. V. Belevich

T. P. Tuzikova

A. V. Goldberg

V. V. Zhdanov

L. A. Miroshnichenko

E. V. Udut

E. V. Simanina

A. M. Dygai

G. N. Zyuz’kov

机构：

[1] E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine,

[2] Research Institute of Oncology,undefined

[3] Tomsk National Research Medical Center,undefined

[4] National Research Tomsk State University,undefined

来源：

Bulletin of Experimental Biology and Medicine | 2017年 / 163卷

关键词：

non-small-cell lung carcinoma; granulocytopoiesis; erythropoiesis; docetaxel; cisplatin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy remained at a high level. Combined therapy pronouncedly activated the key elements of the erythroid and granulocytic hematopoietic lineages leading to accumulation of immature and mature myelokaryocytes in the bone marrow, enlargement of the medullary pool of mature neutrophils, and increase in the count of medullary erythroid and granulocytic precursor cells under conditions of their accelerated maturation.

引用

页码：469 / 474

页数：5

共 50 条

[41] Demonstration of non-small-cell lung carcinoma by indium-111 octreotide scintigraphy
Nguyen, BD
Roarke, MC
CLINICAL NUCLEAR MEDICINE, 2000, 25 (10) : 814 - 816
[42] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
[43] Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer
Spina, R.
Chu, S. Y. Y.
Chatfield, M.
Chen, J.
Tin, M. M.
Boyer, M.
INTERNAL MEDICINE JOURNAL, 2013, 43 (07) : 790 - 797
[44] Nivolumab-refractory patients with advanced non-small-cell lung cancer
Costantini, A.
Fallet, V.
Corny, J.
Friard, S.
Chouaid, C.
Duchemann, B.
Giroux-Leprieur, E.
Taillade, L.
Doucet, L.
Brosseau, S.
Wislez, M.
Tredaniel, J.
Cadranel, J.
LUNG CANCER, 2019, 130 : 128 - 134
[45] Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer
Kim, Young Hak
Yoh, Kiyotaka
Niho, Seiji
Goto, Koichi
Ohmatsu, Hironobu
Kubota, Kaoru
Nishiwaki, Yutaka
RESPIRATORY MEDICINE, 2010, 104 (03) : 434 - 439
[46] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
Lee, Jin Hwa
Lee, Kyoung Eun
Ryu, Yon Ju
Chun, Eun Mi
Chang, Jung Hyun
TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
[47] Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review
Blinman, Prunella
Alam, Mahmood
Duric, Vlatka
McLachlan, Sue-Anne
Stockler, Martin R.
LUNG CANCER, 2010, 69 (02) : 141 - 147
[48] Treatment of Surgically Resectable Non-Small-Cell Lung Cancer in Elderly Patients
Haithcock, Benjamin E.
Stinchcombe, Thomas E.
Socinski, Mark A.
CLINICAL LUNG CANCER, 2009, 10 (06) : 405 - 409
[49] sLAG-3 in non-small-cell lung cancer patients' serum
He, Yayi
Wang, Yan
Zhao, Sha
Zhao, Chao
Zhou, Caicun
Hirsch, Fred R.
ONCOTARGETS AND THERAPY, 2018, 11 : 4781 - 4784
[50] Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients
Takayuki Takimoto
Tasuku Nakabori
Akio Osa
Satomu Morita
Haruko Terada
Susumu Oseto
Takashi Iwazawa
Kinya Abe
International Journal of Clinical Oncology, 2012, 17 : 395 - 398

← 1 2 3 4 5 →